HOUSTON, Feb. 21, 2019 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications,
today announced that Dr. Helen E.
Heslop, Company co-founder and a founding member of Marker's
Scientific Advisory Board, has been recognized with the ASBMT
Lifetime Achievement Award at the Transplantation & Cellular
Therapy Meetings of ASBMT and CIBMTR 2019. The ASBMT Lifetime
Achievement Award is presented annually and recognizes an
individual who has made continuing contributions to the field of
blood and marrow transplantation.
"We would like to congratulate Dr. Heslop on receiving this
lifetime achievement award – one of the highest honors in the field
– in recognition of her contribution to advancing the science in
the field as a leading researcher and innovator in the adoptive T
cell and immunotherapy community," commented Peter L. Hoang, President & CEO of Marker
Therapeutics. "Over the course of her career, Dr. Heslop's
discoveries have led to important advances for patients with a
focus on improved outcomes with hematopoietic stem cell
transplantation and cancer therapy. We are extremely honored to
have Dr. Heslop as an esteemed member of our SAB, where her
expertise and guidance have been instrumental in shaping our
clinical strategy as we advance our pipeline of novel T cell
therapies."
Dr. Heslop, a trained physician-scientist, is Professor of
Medicine and Pediatrics and Director of the Center for Cell and
Gene Therapy at Baylor College of
Medicine, Houston Methodist Hospital and Texas Children's
Hospital. In addition, she is the Dan L Duncan Chair and the
Associate Director of Clinical Research at the Dan L. Duncan Cancer
Center. Dr. Heslop is a key player in translational research
focusing on adoptive T cell immunotherapy to improve hematopoietic
stem cell transplantation and cancer therapy. She was also a Doris
Duke Distinguished Clinical Research Scientist and serves as the
current President elect of the American Society for Gene and Cell
Therapy (ASGCT) and a past President of the Foundation for
Accreditation of Cell Therapy (FACT) and the American Society of
Blood and Marrow Transplantation.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. Once infused into patients,
this population of T cells attacks multiple tumor targets and acts
to activate the patient's immune system to produce broad spectrum
anti-tumor activity. Because Marker does not genetically engineer
its T cells, when compared to current engineered CAR-T and
TCR-based approaches, its products (i) are significantly less
expensive and easier to manufacture, (ii) appear to be markedly
less toxic, and (iii) are associated with meaningful clinical
benefit. As a result, Marker believes its portfolio of T cell
therapies has a compelling therapeutic product profile, as compared
to current gene-modified CAR-T and TCR-based therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase II clinical
trials. In parallel, we are developing a proprietary DNA expression
technology named PolyStart™ that can enhance the ability of the
immune system to recognize and destroy diseased cells.
For additional information, please call toll free at (904)
862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Follow us on Twitter @MRKRTherapeutic, or follow us
on Facebook.
Forward-Looking Statement Disclaimer
This release
contains forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's
expectations, plans, business outlook or future performance, and
any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are
"forward-looking statements". Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research and development activities relating to our
non-engineered multi-tumor antigen specific T cell therapies; our
TPIV200 and TPIV100/110 programs and our PolyStart™ program; the
effectiveness of these programs or the possible range of
application and potential curative effects and safety in the
treatment of diseases; and, the timing and success of our clinical
trials, as well as multi-tumor antigen specific T cell clinical
trials conducted by our collaborators. Forward-looking statements
are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from
those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-congratulates-helen-e-heslop-md-dsc-hon-on-receiving-the-asbmt-lifetime-achievement-award-300800133.html
SOURCE Marker Therapeutics, Inc.